Sergey Shcherbinin

8.3k total citations · 3 hit papers
95 papers, 3.1k citations indexed

About

Sergey Shcherbinin is a scholar working on Radiology, Nuclear Medicine and Imaging, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Sergey Shcherbinin has authored 95 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Radiology, Nuclear Medicine and Imaging, 41 papers in Physiology and 31 papers in Psychiatry and Mental health. Recurrent topics in Sergey Shcherbinin's work include Medical Imaging Techniques and Applications (38 papers), Alzheimer's disease research and treatments (37 papers) and Dementia and Cognitive Impairment Research (28 papers). Sergey Shcherbinin is often cited by papers focused on Medical Imaging Techniques and Applications (38 papers), Alzheimer's disease research and treatments (37 papers) and Dementia and Cognitive Impairment Research (28 papers). Sergey Shcherbinin collaborates with scholars based in United States, Canada and United Kingdom. Sergey Shcherbinin's co-authors include John R. Sims, Mark A. Mintun, Cynthia Evans, Paul Ardayfio, Scott W. Andersen, Albert Lo, Stephen Salloway, A. Ćeller, Alette M. Wessels and Daniel Skovronsky and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Communications.

In The Last Decade

Sergey Shcherbinin

88 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Donanemab in Early Alzheimer’s Disease

2021 969 citations Mark A. Mintun, Albert Lo et al. New England Journal of Medicine profile →
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

2020 292 citations Sergey Shcherbinin, John R. Sims et al. profile →
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease

2022 138 citations Michael J. Pontecorvo, Ming Lu et al. JAMA Neurology profile →

Peers

Countries citing papers authored by Sergey Shcherbinin

Since Specialization

Citations

This map shows the geographic impact of Sergey Shcherbinin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergey Shcherbinin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergey Shcherbinin more than expected).

Fields of papers citing papers by Sergey Shcherbinin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergey Shcherbinin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergey Shcherbinin. The network helps show where Sergey Shcherbinin may publish in the future.

Co-authorship network of co-authors of Sergey Shcherbinin

This figure shows the co-authorship network connecting the top 25 collaborators of Sergey Shcherbinin. A scholar is included among the top collaborators of Sergey Shcherbinin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergey Shcherbinin. Sergey Shcherbinin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Donanemab exposure‐response in early symptomatic Alzheimer's disease 2025 ·Alzheimer s & Dementia ·Ivelina Gueorguieva, Kay Hoong Chow, Laiyi Chua, Sergey Shcherbinin, Jennifer A. Zimmer, C D Evans, Hong Wang, Emel Serap Monkul Nery, Dawn A. Brooks, John R. Sims	5
2	Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial 2025 ·Nature Medicine ·Corby K. Martin, Owen Carmichael, Susan Carnell, Robert V. Considine, David A. Kareken, Ulrike Dydak, Richard D. Mattes, David R. Scott, Sergey Shcherbinin, Hiroshi Nishiyama, Alexander J. Knights, (unknown), (unknown), Edward Pratt, Axel Haupt, Mark A. Mintun, Diana Otero Svaldi, Zvonko Miličević, Tamer Coşkun	6
3	The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 2025 ·The Journal of Prevention of Alzheimer s Disease ·Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, (unknown), Stephen Salloway, Mark A. Mintun, John R. Sims	2
4	Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease 2025 ·JAMA Neurology ·Ming Lu, (unknown), Emily C. Collins, Sergey Shcherbinin, (unknown), Yuma Yokoi, Dawn A. Brooks, Oskar Hansson, David S. Knopman, John R. Sims, Mark A. Mintun	2
5	Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER‐ALZ 3 2025 ·Alzheimer s & Dementia ·R. Yaari, Karen C. Holdridge, (unknown), Alette M. Wessels, Sergey Shcherbinin, (unknown), (unknown), Pierre N. Tariot, Robert Alexander, Jessica B. Langbaum, John R. Sims	4
6	Predicting regional tau accumulation with machine learning‐based tau‐PET and advanced radiomics 2024 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Saima Rathore, Ixavier A. Higgins, Jian Wang, Ian Kennedy, Leonardo Iaccarino, Samantha C. Burnham, Michael J. Pontecorvo, Sergey Shcherbinin	0
7	1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial 2024 ·Age and Ageing ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, (unknown), C D Evans, Ming‐Chi Lu, Paul Ardayfio, Janet D. Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, (unknown), Ellen B. Dennehy, Doug A. Brooks, Daniel Skovronsky, (unknown), (unknown)	2
8	Evaluation of Baseline Diffusion Tensor Imaging Biomarkers in phase 2 multi‐center PROSPECT‐ALZ study 2024 ·Alzheimer s & Dementia ·Diana Otero Svaldi, Saima Rathore, (unknown), Leanne Munsie, Adam Fleisher, Mirosław Bryś, Sergey Shcherbinin	0
9	Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease 2023 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Hoong Chow, C. Steven Ernest, Jian Wang, Sergey Shcherbinin, John R. Sims, Emmanuel Chigutsa	14
10	Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial 2023 ·Alzheimer s & Dementia ·Mark A. Mintun, Craig Ritchie, Paul R. Solomon, John R. Sims, Stephen Salloway, Oskar Hansson, Liana G. Apostolova, Jennifer A. Zimmer, Cynthia Evans, Ming Lu, Paul Ardayfio, JonDavid Sparks, Alette M. Wessels, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Emily C. Collins, Ellen B. Dennehy, Dawn A. Brooks, Daniel Skovronsky	6
11	Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials 2023 ·Alzheimer s & Dementia ·Sergey Shcherbinin, Ivelina Gueorguieva, (unknown), Cynthia Evans, Michael Case, (unknown), Emily C. Collins, Dawn A. Brooks, John R. Sims, Ming‐Chi Lu	3
12	Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease 2023 ·Clinical Pharmacology & Therapeutics ·Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua, Kay Hoong Chow, C. Steven Ernest, Sergey Shcherbinin, Paul Ardayfio, Garrett R. Mullins, John R. Sims	46
13	Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial 2023 ·Journal of Alzheimer s Disease Reports ·Brian A. Willis, Albert Lo, Jeffrey L. Dage, Sergey Shcherbinin, (unknown), Scott W. Andersen, Elizabeth LaBell, David Pérahia, Paula M. Hauck, Stephen L. Lowe	8
14	Distinct associations between tau PET and cognitive impairment across brain regions and cognitive domains in Alzheimer’s disease 2023 ·Alzheimer s & Dementia ·Saima Rathore, Giulia Tronchin, Ixavier A. Higgins, Alette M. Wessels, Leonardo Iaccarino, John R. Sims, Mark A. Mintun, Sergey Shcherbinin	1
15	Preclinical PET Imaging and Toxicity Study of a 68Ga-Functionalized Polymeric Cardiac Blood Pool Agent 2023 ·Pharmaceutics ·Katayoun Saatchi, François Bénard, (unknown), (unknown), Sergey Shcherbinin, Maral Pourghiasian, Donald E. Brooks, A. Ćeller, Urs O. Häfeli	1
16	Donanemab in Early Alzheimer’s Disease breakdown → 2021 ·New England Journal of Medicine ·Mark A. Mintun, Albert Lo, Cynthia Evans, Alette M. Wessels, Paul Ardayfio, Scott W. Andersen, Sergey Shcherbinin, JonDavid Sparks, John R. Sims, Mirosław Bryś, Liana G. Apostolova, Stephen Salloway, Daniel Skovronsky	969
17	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia 2021 ·Journal of Alzheimer s Disease Reports ·Albert Lo, Cynthia Evans, Michele Mancini, Hong Wang, Sergey Shcherbinin, Ming Lu, Fanni Natanegara, Brian A. Willis	22
18	IC‐P‐216: LOBAR CLASSIFICATION OF TAU PET IMAGES IN THE EXPEDITION‐3 TRIAL 2018 ·Alzheimer s & Dementia ·Sergey Shcherbinin, Peng Liu, Adam Fleisher, Karen Sundell, Arnaud Charil, Ming‐Chi Lu, Michael D. Devous, Michael J. Pontecorvo, Mark A. Mintun, Eric Siemers, Michael C. Irizarry, Adam J. Schwarz	1
19	Kinetics of the Tau PET Tracer ¹⁸F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease 2016 ·Journal of Nuclear Medicine ·Sergey Shcherbinin, Adam J. Schwarz, Abhinay D. Joshi, Michael Navitsky, Matthew Flitter, William R. Shankle, Michael D. Devous, Mark A. Mintun	80
20	An innovative iterative thresholding algorithm for tumour segmentation and volumetric quantification on SPECT images: Monte Carlo-based methodology and validation 2011 ·Medical Physics ·Massimiliano Pacilio, (unknown), Sergey Shcherbinin, Federica Caselli, Guido Ventroni, (unknown), Lucio Mango, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact